Despite growing urgency around climate-smart agriculture and industrial decarbonization, microbial technologies must navigate a fragmented and evolving regulatory landscape that reflects legitimate safety and efficacy considerations.
A product approved in one region may require years of re-evaluation elsewhere. Definitions vary, timelines differ across jurisdictions, and many frameworks are still adapting to the specificities of living organisms.
One product, many pathways
Consider the case of a single microbial consortium designed for soil fertility. In the European Union, it may fall under the Plant Protection Products Regulation (EC 1107/2009), a framework originally designed for chemical pesticides. In the United States, it might be reviewed by the Environmental Protection Agency (EPA) under different categories depending on its intended claims. In Latin America, it could face a combination of federal and state-level reviews with limited harmonization.
These differences create significant administrative complexity. Companies must tailor documentation, data formats, safety testing, and even product formulations for each jurisdiction. For startups and Small and Medium-sized Enterprises (SMEs), the cost and time involved can make global expansion challenging.
What makes regulating microbes so complex?
Unlike chemicals, microbes do not follow a single, predictable mode of action. Many remain inactive until triggered by specific plant signals or interactions with other microorganisms. In fact, in many cases, the organisms are already present in the environment on plants, in soil, or even imported on food but at lower concentrations or in less effective strains.
Microbes travel across borders on all fruit, vegetation, soils… Regulate that. Many are universally present. Trying to control them with frameworks made for chemicals is like measuring wind with a ruler.
A telling case is that of Gluconacetobacter diazotrophicus, a beneficial bacterium originally isolated from sugarcane. Although this microbe occurs naturally and was recoverable at extremely high concentrations from imported sugarcane sold in grocery stores, it still took nearly 6 months to secure regulatory approval in Canada. This highlights how careful and detailed evaluations can be when dealing with naturally occurring microorganisms.
Three systemic bottlenecks
- Evolving regulatory categories
Many existing frameworks are gradually evolving to better assess complex biological systems, as new genomic and metagenomic tools become available. Microbes are dynamic, context-dependent, and interactive. For example, a microbial product containing five strains must demonstrate the presence of each at a defined level. If each strain were submitted separately, they would need to go through five independent assessments even if identical in formulation. This reflects the rigor and depth of current evaluation processes. - Lack of mutual recognition
A dossier accepted by one country rarely speeds up approval in another. This lack of harmonization can slow international scalability, especially for smaller companies. In some U.S. states, approval may take just one month, while in California it can extend beyond two years. The EU is attempting to standardize its approach by placing long-established microbial species such as Rhizobia and Mycorrhiza on “safe lists.” Internationally, coordination is improving through scientific exchange and regulator supplier collaboration. - Extended evaluation timelines
Regulatory evaluation can take time, as agencies and suppliers perform detailed analyses to ensure the long-term safety and functionality of microbial strains before authorization. This may include genome sequencing, toxicity and antibiotic-resistance studies, and confirmation of beneficial functions through experimentation. Such rigor ensures that future applications remain safe, sustainable, and scientifically validated.
What this means for the industry
For companies developing microbial solutions, these regulatory processes require anticipation, planning, and close collaboration with authorities. While they may postpone commercialization, they do not hinder scientific innovation. On the contrary, researchers continue to explore microbial diversity and conduct pilot-scale trials that demonstrate new potential for industrial scale applications.
These efforts strengthen confidence in biological products and support the emergence of a safer, more transparent bioeconomy.
The case for reform
Progress will depend on continued dialogue and collaboration among all stakeholders:
- Clearer, biology-specific categories that reflect the nature and behavior of microbial products
- Mutual recognition frameworks or fast-track mechanisms between aligned jurisdictions
- Regulator-scientist collaboration to evolve evaluation criteria and integrate new risk assessment tools
- Capacity-building in regions where regulatory bodies lack specific microbial expertise
- Investment in infrastructure for SMEs to scale biosolution production
- Better distinction between food cultures and microbial inputs to avoid counterproductive classifications
How Proventus navigates the maze
At Proventus, we approach regulation as a design constraint not an afterthought.
From the earliest stages of R&D, we integrate the regulatory requirements of our target markets into strain selection, formulation strategies, and data generation protocols.
We also collaborate closely with partners and clients to prepare documentation that anticipates regional needs, reducing time-to-approval and ensuring compliance without compromising biological efficacy.
We believe that regulatory diligence and scientific innovation go hand in hand. With the right design mindset and collaborative approach, regulation becomes not a barrier, but a pathway toward global trust, safety, and impact.
We believe regulatory complexity shouldn’t be a barrier to microbial progress. With the right design mindset and collaborative approach, it can become a lever for global trust, safety, and impact.